Colin Ng & Partners LLP (“CNP”) advised and acted as solicitors for Fund Singapore on a Pre-IPO investment round of Biolidics Limited (the “Biolidics”). Biolidics has successfully listed on the Catalist Board of the Singapore Exchange on 19 December 2018.
The IPO launch is set to raise approximately S$6.1 million in net proceeds from which, proceeds will be used in developing the company’s clinical services applications and customer segment of Biolidics’ products. It will also advance its pipeline products through in-house development, investments, mergers and acquisitions, joint ventures and/or strategic collaborations.
Mr Christopher Huang (Partner), Mr Randall Perera (Senior Associate) and Mr Rajkumar Mannar (Associate) advised Fund Singapore on the negotiation of the pre-IPO series C investment as well as the corporate governance issue and disposal of shares upon IPO.